Saturday 17 October 2026
Export CAMP’s income statement to Excel — free account
CAMP4 Therapeutics Corporation
CAMP Healthcare Biotechnology
CAMP4 Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, up 436.5% from fiscal 2024. In the quarter to June 2026, revenue grew 18.8%, EPS grew 6.45% and free cash flow fell 23.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.17
0.28
−8.12%
Follow CAMP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.05 |
+8 more quarters Free account |
P/S ratio |
60.05 | 64.93 | 53.24 | 23.38 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(19.96) | (23.26) | 29.59 | (7.29) | |
P/B ratio |
0.00 | 8.27 | 3.90 | 1.39 | |
Price to Tangible BV |
0.00 | 8.27 | 3.90 | 1.39 | |
EV/Sales |
39.39 | 39.54 | 21.56 | 1.89 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.81) | (5.93) | (2.55) | (0.14) | |
EV/FCF |
(5.79) | (5.87) | (2.53) | (0.14) | |
Quick Ratio |
4.55 | 6.01 | 7.15 | 9.52 | |
Current Ratio |
4.70 | 6.15 | 7.35 | 9.83 | |
Net Debt/EBITDA |
6.77 | 7.96 | 8.94 | 5.68 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.05% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.06 | 0.05 | 0.04 | 0.07 | |
Operating CF/Net income |
0.38 | 0.60 | (0.16) | 0.74 | |
Capex/Depreciation |
(0.25) | 0.00 | 0.00 | 0.09 | |
Research and Development Expense of Revenue |
608.04% | 785.16% | 2,401.44% | 1,176.86% | |
Selling, General and Administrative Expense of Revenue |
244.07% | 324.96% | 1,369.83% | 578.11% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
108.54% | 113.76% | 330.75% | 123.77% | |
Graham Net Nets |
(0.02) | 0.11 | 0.24 | 0.61 | |
Graham Number |
0.79 | 0.00 | 0.00 | 55.62 | |
Earnings Yield |
(53.09%) | (53.51%) | (43.39%) | 2,130.89% | |
Free Cash Flow Yield |
(11.33%) | (10.37%) | (16.00%) | (58.22%) | |
Revenue per Share |
0.03 | 0.02 | 0.01 | 0.03 | |
Operating CF per Share |
(0.22) | (0.19) | 0.21 | (0.41) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.22) | (0.19) | 0.21 | (0.41) | |
Cash per Share |
1.50 | 1.73 | 3.65 | 2.76 | |
Shareholders Equity per Share |
(0.01) | 0.53 | 1.57 | 2.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.01) | 0.53 | 1.57 | 2.15 | |
Free Cash Flow |
(12.81) | (10.98) | 6.29 | (11.18) | |
Working Capital |
70.89 | 85.57 | 98.58 | 69.81 | |
Capital Expenditures |
(0.13) | — | 0.00 | 0.04 | |
Net Current Asset Value |
(4.09) | 27.64 | 43.99 | 49.98 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.07 | 0.00 | 0.00 | (0.05) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.14 | 1.13 | 0.70 | 2.23 | |
Average Assets |
72.35 | 84.12 | 98.06 | 53.88 | |
Average Common Equity |
19.65 | 41.24 | 55.42 | (50.15) |
Columns are period end dates